DOI QR코드

DOI QR Code

Associations of unspecified pain, idiopathic pain and COVID-19 in South Korea: a nationwide cohort study

  • Kim, Namwoo (Department of Neuropsychiatry, Seoul National University Hospital) ;
  • Kim, Jeewuan (Department of Statistics and Data Science, Yonsei University) ;
  • Yang, Bo Ram (College of Pharmacy, Chungnam National University) ;
  • Hahm, Bong-Jin (Department of Neuropsychiatry, Seoul National University Hospital)
  • Received : 2022.05.04
  • Accepted : 2022.06.30
  • Published : 2022.10.01

Abstract

Background: Few studies have investigated unspecified or idiopathic pain associated with COIVD-19. This study aimed to provide the incidence rates of unspecified pain and idiopathic pain in patients with COVID-19 for 90 days after COVID-19 diagnosis. Methods: A propensity score matched cohort was used, including all patients with COVID-19 in South Korea, and analyzed their electronic medical records. The control group consisted of those who had not had tests for COVID-19 at all. Unspecified pain diagnoses consisted of diagnoses related to pain included in the ICD-10 Chapter XVIII. Idiopathic pain disorders included fibromyalgia, temporomandibular joint disorders, headaches, chronic prostatitis, complex regional pain syndrome, atypical facial pain, irritable bowel syndrome, and interstitial cystitis. Results: After matching, the number of participants in each group was 7,911. For most unspecified pain, the incidences were higher in the COVID-19 group (11.7%; 95% confidence interval [CI], 11.0-12.5) than in the control group (6.5%; 95% CI, 6.0-7.1). For idiopathic pain, only the headaches had a significantly higher incidence in the COVID-19 group (6.6%; 95% CI, 6.1-7.2) than in the control group (3.7%; 95% CI, 3.3-4.1). However, using a different control group that included only patients who visited a hospital at least once for any reasons, the incidences of most unspecified and idiopathic pain were higher in the control group than in the COVID-19 group. Conclusions: Patients with COVID-19 might be at a higher risk of experiencing unspecified pain in the acute phase or after recovery compared with individuals who had not had tests for COVID-19.

Keywords

Acknowledgement

We would like to thank all staff members of the National Health Insurance Sharing Service.

References

  1. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med 2021; 385: 585-94. https://doi.org/10.1056/NEJMoa2108891
  2. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020; 7: 611-27. https://doi.org/10.1016/S2215-0366(20)30203-0
  3. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol 2020; 19: 767-83. https://doi.org/10.1016/s1474-4422(20)30221-0
  4. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11: 16144. https://doi.org/10.1038/s41598-021-95565-8
  5. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020; 143: 3104-20. https://doi.org/10.1093/brain/awaa240
  6. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220-32. https://doi.org/10.1016/S0140-6736(20)32656-8
  7. Koseoglu Toksoy C, DemirbasH, Bozkurt E, Acar H, Turk Boru u. Headache related to mask use of healthcare workers in COVID-19 pandemic. Korean J Pain 2021; 34: 241-5. https://doi.org/10.3344/kjp.2021.34.2.241
  8. Clauw DJ, Hauser W, Cohen SP, Fitzcharles MA. Considering the potential for an increase in chronic pain after the CO-VID-19 pandemic. Pain 2020; 161: 1694-7. https://doi.org/10.1097/j.pain.0000000000001950
  9. Chaturvedi SK. Health anxiety, health-related life events, and somatization during COVID-19 pandemic can increase chronic pain. Pain 2020; 161: 2652. https://doi.org/10.1097/j.pain.0000000000002061
  10. Karos K, McParland JL, Bunzli S, Devan H, Hirsh A, Kapos FP, et al. The social threats of COVID-19 for people with chronic pain. Pain 2020; 161: 2229-35. https://doi.org/10.1097/j.pain.0000000000002004
  11. Drozdzal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Majewski P, et al. COVID-19: pain management in patients with SARS-CoV-2 infection-molecular mechanisms, challenges, and perspectives. Brain Sci 2020; 10: 465. https://doi.org/10.3390/brainsci10070465
  12. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a singlecentre longitudinal study. Clin Microbiol Infect 2021; 27: 89-95. https://doi.org/10.1016/j.cmi.2020.09.023
  13. CarfiA, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324: 603-5. https://doi.org/10.1001/jama.2020.12603
  14. Mun CJ, Campbell CM, McGill LS, Aaron RV. The early impact of COVID-19 on chronic pain: a cross-sectional investigation of a large online sample of individuals with chronic pain in the United States, April to May, 2020. Pain Med 2021; 22: 470-80. https://doi.org/10.1093/pm/pnaa446
  15. Nunes EV, Levin FR, Reilly MP, El-Bassel N. Medication treatment for opioid use disorder in the age of COVID-19: can new regulations modify the opioid cascade? J Subst Abuse Treat 2021; 122: 108196. https://doi.org/10.1016/j.jsat.2020.108196
  16. Kim N, Cho SJ, Kim H, Kim SH, Lee HJ, Park CHK, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea. PLoS One 2019; 14: e0221552. https://doi.org/10.1371/journal.pone.0221552
  17. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014; 36: e2014008. https://doi.org/10.4178/epih/e2014008
  18. World Health Organization. ICD-10: international statistical classification of diseases and related health problems: tenth revision. 2nd ed. Geneva, World Health Organization. 2004.
  19. Diatchenko L, Nackley AG, Slade GD, Fillingim RB, Maixner W. Idiopathic pain disorders--pathways of vulnerability. Pain 2006; 123: 226-30. https://doi.org/10.1016/j.pain.2006.04.015
  20. McMichael TM, Currie DW, Clark S, Pogosjans S, Kay M, Schwartz NG, et al. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N Engl J Med 2020; 382: 2005-11. https://doi.org/10.1056/NEJMoa2005412
  21. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021; 8: 416-27. https://doi.org/10.1016/S2215-0366(21)00084-5
  22. Komaroff AL, Bateman L. Will COVID-19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne) 2021; 7: 606824. https://doi.org/10.3389/fmed.2020.606824
  23. Vollbracht C, Kraft K. Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients 2021; 13: 1154. https://doi.org/10.3390/nu13041154
  24. Shorey S, Chan V. Lessons from past epidemics and pandemics and a way forward for pregnant women, midwives and nurses during COVID-19 and beyond: a meta-synthesis. Midwifery 2020; 90: 102821. https://doi.org/10.1016/j.midw.2020.102821
  25. Mueller C, Lin JC, Sheriff S, Maudsley AA, Younger JW. Evidence of widespread metabolite abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome: assessment with whole-brain magnetic resonance spectroscopy. Brain Imaging Behav 2020; 14: 562-72. https://doi.org/10.1007/s11682-018-0029-4
  26. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers 2017; 3: 17002. https://doi.org/10.1038/nrdp.2017.2
  27. Alizadeh R, Aghsaeifard Z. Does COVID19 activates previous chronic pain? A case series. Ann Med Surg (Lond) 2021; 61: 169-71. https://doi.org/10.1016/j.amsu.2020.12.045
  28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, American Psychiatric Publishing. 2013.
  29. Poveda Roda R, Bagan JV, Diaz Fernandez JM, Hernandez Bazan S, Jimenez Soriano Y. Review of temporomandibular joint pathology. Part I: classification, epidemiology and risk factors. Med Oral Patol Oral Cir Bucal 2007; 12: E292-8.
  30. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160: 221-36. https://doi.org/10.1176/appi.ajp.160.2.221
  31. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 2020; 15: e0240784. https://doi.org/10.1371/journal.pone.0240784